GenTrust’s Neurocrine Biosciences NBIX Stock Holding History

GenTrust’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$335K	Buy	2,541 +781	+44%	+$104K	0.01%	191
2025 Q4	$250K	Buy	+1,760	New	+$255K	0.01%	239

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GenTrust's NBIX Position: Q1 2026 in Review

GenTrust increased its Neurocrine Biosciences (NBIX) stake by 44% in Q1 2026, buying an estimated $104K and bringing the position to 2,541 shares worth $335K. The position accounts for 0.01% of the portfolio, ranked #191.

GenTrust first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

GenTrust held 2,541 shares of Neurocrine Biosciences worth $335K as of Q1 2026.
GenTrust bought 781 Neurocrine Biosciences shares in Q1 2026, an estimated $104K.
Neurocrine Biosciences made up 0.01% of GenTrust's portfolio in Q1 2026, its #191 holding.
GenTrust first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on GenTrust's 13F filing for Q1 2026, filed 27 Apr 2026.